Subscribe for free to our flagship newsletter, CDR: This Week in Retail, for news and insights from the voice of retail pharmacy.

Skip to content

Camber launches sirolimus oral solution

Sirolimus oral solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.

Table of Contents

PISCATAWAY, N.J. — Camber Pharmaceuticals announces the addition of Sirolimus oral solution.

Sirolimus oral solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.

  • Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
  • Patients at high immunologic risk: use in combination with CsA and corticosteroids

Sirolimus oral solution 1 mg/mL is now available in a 60 mL bottle.

To find out more information on sirolimus oral solution, visit: www.camberpharma.com/sirolimus

Comments

Latest